This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dey, B.
Right arrow Articles by Berger, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dey, B.
Right arrow Articles by Berger, E. A.

 Previous Article  |  Next Article 

Journal of Virology, May 2000, p. 4562-4569, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses

Barna Dey,1 Danica L. Lerner,2 Paolo Lusso,3 Michael R. Boyd,4 John H. Elder,2 and Edward A. Berger1,*

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-04451; Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 920372; Unit of Human Virology, Department of Biological and Technological Research, San Raffaele Scientific Institute, 20132 Milan, Italy3; and Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 217024

Received 14 September 1999/Accepted 16 February 2000

Cyanovirin-N (CV-N) is a cyanobacterial protein with potent neutralizing activity against human immunodeficiency virus (HIV). CV-N has been shown to bind HIV type 1 (HIV-1) gp120 with high affinity; moreover, it blocks the envelope glycoprotein-mediated membrane fusion reaction associated with HIV-1 entry. However, the inhibitory mechanism(s) remains unclear. In this study, we show that CV-N blocked binding of gp120 to cell-associated CD4. Consistent with this, pretreatment of gp120 with CV-N inhibited soluble CD4 (sCD4)-dependent binding of gp120 to cell-associated CCR5. To investigate possible effects of CV-N at post-CD4 binding steps, we used an assay that measures sCD4 activation of the HIV-1 envelope glycoprotein for fusion with CCR5-expressing cells. CV-N displayed equivalently potent inhibitory effects when added before or after sCD4 activation, suggesting that CV-N also has blocking action at the level of gp120 interaction with coreceptor. This effect was shown not to be due to CV-N-induced coreceptor down-modulation after the CD4 binding step. The multiple activities against the HIV-1 envelope glycoprotein prompted us to examine other enveloped viruses. CV-N potently blocked infection by feline immunodeficiency virus, which utilizes the chemokine receptor CXCR4 as an entry receptor but is CD4 independent. CV-N also inhibited fusion and/or infection by human herpesvirus 6 and measles virus but not by vaccinia virus. Thus, CV-N has broad-spectrum antiviral activity, both for multiple steps in the HIV entry mechanism and for diverse enveloped viruses. This broad specificity has implications for potential clinical utility of CV-N.

* Corresponding author. Mailing address: Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Building 4, room 237, National Institutes of Health, Bethesda, MD 20892. Phone: (301) 402-2481. Fax: (301) 480-1147. E-mail: edward_berger{at}nih.gov.

Journal of Virology, May 2000, p. 4562-4569, Vol. 74, No. 10
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff, C. P., Akkina, R., Rossi, J. J. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109 [Abstract] [Full Text]  
  • Hori, K., Sato, Y., Ito, K., Fujiwara, Y., Iwamoto, Y., Makino, H., Kawakubo, A. (2007). Strict specificity for high-mannose type N-glycans and primary structure of a red alga Eucheuma serra lectin. Glycobiology 17: 479-491 [Abstract] [Full Text]  
  • Barrientos, L. G., Matei, E., Lasala, F., Delgado, R., Gronenborn, A. M. (2006). Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein Eng Des Sel 19: 525-535 [Abstract] [Full Text]  
  • Liu, X., Lagenaur, L. A., Simpson, D. A., Essenmacher, K. P., Frazier-Parker, C. L., Liu, Y., Tsai, D., Rao, S. S., Hamer, D. H., Parks, T. P., Lee, P. P., Xu, Q. (2006). Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.. Antimicrob. Agents Chemother. 50: 3250-3259 [Abstract] [Full Text]  
  • Pashov, A., MacLeod, S., Saha, R., Perry, M., VanCott, T. C., Kieber-Emmons, T. (2005). Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994-1001 [Abstract] [Full Text]  
  • Moore, J. P., Shattock, R. J. (2003). Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?. J Antimicrob Chemother 52: 890-892 [Full Text]  
  • Vermeire, K., Schols, D. (2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol. 74: 667-675 [Abstract] [Full Text]  
  • O'Keefe, B. R., Smee, D. F., Turpin, J. A., Saucedo, C. J., Gustafson, K. R., Mori, T., Blakeslee, D., Buckheit, R., Boyd, M. R. (2003). Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin. Antimicrob. Agents Chemother. 47: 2518-2525 [Abstract] [Full Text]  
  • Hong, P. W.-P., Flummerfelt, K. B., de Parseval, A., Gurney, K., Elder, J. H., Lee, B. (2002). Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding. J. Virol. 76: 12855-12865 [Abstract] [Full Text]  
  • Botos, I., O'Keefe, B. R., Shenoy, S. R., Cartner, L. K., Ratner, D. M., Seeberger, P. H., Boyd, M. R., Wlodawer, A. (2002). Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides. J. Biol. Chem. 277: 34336-34342 [Abstract] [Full Text]  
  • Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., Moore, J. P. (2002). The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. J. Virol. 76: 7293-7305 [Abstract] [Full Text]  
  • Beutler, J. A., McMahon, J. B., Johnson, T. R., O'Keefe, B. R., Buzzell, R. A., Robbins, D., Gardella, R., Wilson, J., Boyd, M. R. (2002). High Throughput Screening for Cyanovirin-N Mimetics Binding to HIV-1 gp4l. J Biomol Screen 7: 105-110 [Abstract]  
  • Bolmstedt, A. J., O'Keefe, B. R., Shenoy, S. R., McMahon, J. B., Boyd, M. R. (2001). Cyanovirin-N Defines a New Class of Antiviral Agent Targeting N-Linked, High-Mannose Glycans in an Oligosaccharide-Specific Manner. Mol. Pharmacol. 59: 949-954 [Abstract] [Full Text]  
  • Shenoy, S. R., O'Keefe, B. R., Bolmstedt, A. J., Cartner, L. K., Boyd, M. R. (2001). Selective Interactions of the Human Immunodeficiency Virus-Inactivating Protein Cyanovirin-N with High-Mannose Oligosaccharides on gp120 and Other Glycoproteins. J. Pharmacol. Exp. Ther. 297: 704-710 [Abstract] [Full Text]  
  • Mori, T., Boyd, M. R. (2001). Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. Antimicrob. Agents Chemother. 45: 664-672 [Abstract] [Full Text]  
  • O'Keefe, B. R., Shenoy, S. R., Xie, D., Zhang, W., Muschik, J. M., Currens, M. J., Chaiken, I., Boyd, M. R. (2000). Analysis of the Interaction between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41. Mol. Pharmacol. 58: 982-992 [Abstract] [Full Text]  
  • D'Souza, M. P., Cairns, J. S., Plaeger, S. F. (2000). Current Evidence and Future Directions for Targeting HIV Entry: Therapeutic and Prophylactic Strategies. JAMA 284: 215-222 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»